Tinavi Medical Technologies Co Ltd

688277 · SHG · Healthcare / Medical Instruments & Supplies

14.61CNY-0.52 (-3.44%)

Price History

Full chart

Market Stats

Previous Close15.13

Open15.16

Day Range14.49 – 15.39

52-Week Range14.14 – 29.05

Volume5.24M

Market Cap7.30B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.42

Dividend Yield0.00%

Beta0.54

50-Day Avg16.28

200-Day Avg19.58

About

Tinavi Medical Technologies Co., Ltd., together with its subsidiaries, provides orthopedic surgical robots and related technologies in China. The company offers TiRobot II, an orthopedic robotic system that creates an operation center; TiRobot, an orthopedic robotic system that positions surgical instruments and implants in surgery on spine and trauma; 5G remote surgery system; TiRobot instruments, including hand surgery locating, cervical surgery, hip surgery, and foot and ankle surgery toolkits; and robotic-guided orthopedic surgical system. It is also involved in technical services; and investment management. The company was founded in 2005 and is headquartered in Beijing, China.

Company Details

SectorHealthcare
IndustryMedical Instruments & Supplies
CEOMr. Jin Xu
Employees323
HeadquartersBuilding 2, Courtyard 8, Beijing, China, 100096, China
Websitehttps://www.tinavi.com

Leadership

Mr. Jin XuGM & Director · b. 1974
Mr. Min MaPresident & Director · b. 1967
Ms. Min QiFinancial Director & Accounting Supervisor · b. 1982
Mr. Junhui HuangBoard Secretary · b. 1977
Mr. Tiechang LiuDeputy General Manager · b. 1975

Financials

Income Statement

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	41.76M	38.77M	23.98M	25.58M	73.29M	126.72M	229.56M	135.91M	156.02M	156.19M	210.04M	178.84M	283.26M
Growth (%)	-	-7.16%	-38.16%	+6.68%	+186.58%	+72.89%	+81.16%	-40.80%	+14.80%	+0.11%	+34.48%	-14.85%	+58.38%
Cost of Revenue	19.72M	29.76M	12.93M	14.56M	24.03M	30.41M	34.67M	31.72M	50.04M	54.02M	71.11M	54.18M	85.81M
Gross Profit	22.04M	9.01M	11.04M	11.02M	49.26M	96.31M	194.89M	104.19M	105.98M	102.17M	138.92M	124.66M	283.26M
Gross Margin	52.79%	23.23%	46.05%	43.08%	67.21%	76.00%	84.90%	76.66%	67.93%	65.42%	66.14%	69.70%	100.00%
Operating Expense	27.28M	29.59M	35.49M	45.01M	36.61M	104.40M	234.36M	168.33M	210.46M	246.10M	289.32M	223.96M	444.08M
Operating Income	-5.23M	-20.58M	-24.45M	-33.99M	12.65M	-8.09M	-39.47M	-64.14M	-104.48M	-143.93M	-150.40M	-99.30M	-160.83M
Operating Margin	-12.53%	-53.08%	-101.98%	-132.91%	17.26%	-6.38%	-17.19%	-47.19%	-66.97%	-92.15%	-71.61%	-55.52%	-56.78%
EBITDA	-2.02M	-17.76M	-26.13M	-35.82M	-16.44M	-30.69M	-58.98M	-92.31M	-130.04M	-157.52M	-187.60M	-125.83M	-128.93M
EBITDA Margin	-4.83%	-45.80%	-108.98%	-140.07%	-22.43%	-24.22%	-25.69%	-67.92%	-83.35%	-100.85%	-89.32%	-70.36%	-45.52%
Net Income	6.31M	-15.76M	-15.45M	-25.73M	21.67M	-855.98K	-30.96M	-54.47M	-79.93M	-110.58M	-156.39M	-121.13M	-184.03M
Net Income Margin	15.10%	-40.66%	-64.44%	-100.59%	29.56%	-0.68%	-13.49%	-40.08%	-51.23%	-70.80%	-74.46%	-67.73%	-64.97%
R&D	9.95M	10.29M	14.49M	16.33M	22.29M	41.49M	77.01M	74.11M	109.79M	122.64M	140.32M	85.60M	123.17M
R&D as % of Total Revenue	23.83%	26.54%	60.42%	63.85%	30.42%	32.74%	33.55%	54.53%	70.37%	78.52%	66.81%	47.86%	43.48%
Interest Expense	299.89K	451.65K	-	-	28.41K	287.90K	71.62K	62.54K	3.40M	3.99M	6.43M	9.24M	12.16M
Interest Expense % of Total Revenue	0.72%	1.16%	-	-	0.04%	0.23%	0.03%	0.05%	2.18%	2.55%	3.06%	5.17%	4.29%

Balance Sheet

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	41.36M	67.09M	211.96M	185.77M	622.67M	662.66M	713.60M	1.12B	1.28B	1.41B	1.62B	1.69B	1.71B
Total Liabilities	11.76M	14.25M	7.98M	49.16M	453.26M	102.05M	117.26M	92.73M	211.48M	289.39M	381.95M	411.58M	-1.29B
Total Equity	29.60M	52.84M	164.90M	136.62M	158.49M	550.80M	585.35M	996.03M	1.01B	1.04B	1.24B	1.27B	1.29B
Cash	6.16M	16.55M	72.72M	37.32M	477.37M	281.65M	152.63M	468.40M	287.11M	211.39M	310.86M	260.20M	264.15M
Total Debt	620.72K	6.85M	-	-	-	-	-	29.91M	70.76M	98.42M	194.31M	176.41M	-
Net Debt	-5.54M	-9.71M	-72.72M	-37.32M	-477.37M	-281.65M	-152.63M	-438.50M	-216.35M	-112.97M	-90.97M	-83.79M	-

Cash Flow

Currency: CNY	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-3.38M	-33.84M	41.82M	-32.70M	5.73M	13.15M	20.53M	-57.58M	-77.76M	-87.51M	-170.50M	-98.65M	-51.17M
Investing Cash Flow	406.21K	-542.88K	-106.58M	-2.71M	23.02M	-217.63M	-147.08M	-99.76M	-98.73M	9.62M	-258.17M	75.74M	-
Financing Cash Flow	-4.70M	44.77M	120.93M	-	411.30M	8.76M	-2.47M	473.11M	-4.80M	1.30M	528.30M	-1.79M	-
Capital Expenditure	682.48K	542.88K	1.63M	2.92M	6.28M	27.36M	20.17M	132.17M	238.66M	59.58M	221.03M	36.69M	29.71M
Free Cash Flow	-4.06M	-34.38M	40.19M	-35.62M	-547.71K	-14.21M	359.73K	-189.75M	-316.42M	-147.08M	-391.53M	-135.34M	-80.88M
Dividends Paid	315.97K	456.34K	-	-	-	-	-	-	-	757.80K	4.68M	9.06M	7.18M
FCF to OCF	120.19%	101.60%	96.10%	108.92%	-9.56%	-108.01%	1.75%	329.55%	406.94%	168.08%	229.64%	137.19%	158.07%
Dividend Paid to FCF	-7.78%	-1.33%	-	-	-	-	-	-	-	-0.52%	-1.20%	-6.70%	-8.87%

Earnings

Report Date	Sep 30, 2020	Dec 31, 2020	Apr 28, 2021	Aug 26, 2021	Oct 28, 2021	Dec 31, 2021	Apr 26, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Aug 25, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-0.02
EPS Actual	-0.04	-0.01	-0.06	-0.03	-0.06	-0.04	-0.07	-0.04	-0.09	-0.07	0.02	-0.05
Surprise	-	-	-	-	-	-	-	-	-	-	-	-150.00%
Timing	-	-	-	-	-	-	Pre-market	-	-	-	-	Pre-market

Key Statistics & Ratios

Market Cap7.30B

Enterprise Value7.33B

Trailing P/E0.00

Forward P/E0.00

Price / Sales28.19

Price / Book6.19

EPS-0.42

Book Value2.56

Revenue (TTM)258.77M

Gross Profit (TTM)170.74M

EBITDA-170.81M

Profit Margin-75.47%

Operating Margin-95.04%

Return on Equity-16.81%

Return on Assets-7.78%

Shares Outstanding466.44M

Shares Float326.78M

Beta0.54

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%